Tisotumab vedotin is a human monoclonal antibody conjugate which is used in the therapy of refractory, recurrent or metastatic cervical cancer. Tisotumab vedotin has been linked to transient mild-to-moderate serum aminotransferase elevations during therapy but has not been implicated in cases of liver injury with jaundice.